Annexon Biosciences (NASDAQ: ANNX), a biopharmaceutical company focused on developing novel therapies for classical complement-mediated neuroinflammatory diseases, has announced its participation in the upcoming Jefferies Global Healthcare Conference. Douglas Love, the company's president and CEO, will deliver a presentation on June 4, 2025, at 8:10 a.m. EST. Investors and interested parties can access the live webcast through the 'Events & Presentations' section on Annexon's investor relations website. The presentation recording will remain available for replay on www.annexonbio.com for 30 days after the event.
Annexon Biosciences (NASDAQ: ANNX), una società biofarmaceutica specializzata nello sviluppo di nuove terapie per malattie neuroinfiammatorie mediate dal complemento classico, ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference. Douglas Love, presidente e CEO dell'azienda, terrà una presentazione il 4 giugno 2025 alle 8:10 EST. Investitori e interessati potranno seguire la diretta streaming attraverso la sezione 'Events & Presentations' sul sito web per gli investitori di Annexon. La registrazione della presentazione sarà disponibile in replay su www.annexonbio.com per 30 giorni dopo l'evento.
Annexon Biosciences (NASDAQ: ANNX), una compañía biofarmacéutica enfocada en el desarrollo de terapias novedosas para enfermedades neuroinflamatorias mediadas por el complemento clásico, ha anunciado su participación en la próxima Conferencia Global de Salud de Jefferies. Douglas Love, presidente y CEO de la compañía, realizará una presentación el 4 de junio de 2025 a las 8:10 a.m. EST. Los inversores y personas interesadas podrán acceder a la transmisión en vivo a través de la sección 'Events & Presentations' en el sitio web de relaciones con inversores de Annexon. La grabación de la presentación estará disponible para reproducción en www.annexonbio.com durante 30 días después del evento.
Annexon Biosciences(NASDAQ: ANNX)는 고전 보체 매개 신경염증 질환을 위한 혁신적인 치료법 개발에 주력하는 생명공학 회사로, 다가오는 Jefferies 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 사장 겸 CEO인 Douglas Love가 2025년 6월 4일 오전 8시 10분(EST)에 발표를 진행할 예정입니다. 투자자 및 관심 있는 분들은 Annexon 투자자 관계 웹사이트의 'Events & Presentations' 섹션을 통해 생중계 웹캐스트에 접속할 수 있습니다. 발표 녹화는 행사 후 30일 동안 www.annexonbio.com에서 다시 보기로 제공됩니다.
Annexon Biosciences (NASDAQ : ANNX), une société biopharmaceutique spécialisée dans le développement de nouvelles thérapies pour les maladies neuro-inflammatoires médiées par le complément classique, a annoncé sa participation à la prochaine conférence mondiale Jefferies Global Healthcare Conference. Douglas Love, président et CEO de la société, présentera le 4 juin 2025 à 8h10 EST. Les investisseurs et parties intéressées pourront accéder à la diffusion en direct via la section « Events & Presentations » du site web des relations investisseurs d’Annexon. L’enregistrement de la présentation restera disponible en replay sur www.annexonbio.com pendant 30 jours après l’événement.
Annexon Biosciences (NASDAQ: ANNX), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung neuartiger Therapien für klassische komplementvermittelte neuroinflammatorische Erkrankungen spezialisiert hat, hat seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference angekündigt. Douglas Love, Präsident und CEO des Unternehmens, wird am 4. Juni 2025 um 8:10 Uhr EST eine Präsentation halten. Investoren und Interessierte können den Live-Webcast über den Bereich 'Events & Presentations' auf der Investor-Relations-Website von Annexon verfolgen. Die Aufzeichnung der Präsentation wird für 30 Tage nach der Veranstaltung auf www.annexonbio.com zum Abruf bereitstehen.
Positive
None.
Negative
None.
BRISBANE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 8:10 a.m. EST.
A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.
About Annexon Annexon Biosciences (Nasdaq: ANNX) is developing therapeutics that stop classical complement-driven neuroinflammation as first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting C1q, our immunotherapies are designed to stop this neuroinflammatory cascade in disease before it starts. Our pipeline spans three diverse therapeutic areas – autoimmune, neurodegenerative and ophthalmic diseases – and includes targeted investigational drug candidates designed to address the unmet needs of over 8 million people worldwide. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.